Literature DB >> 18788635

[Expression and clinical significance of HMGB1 and RAGE in cervical squamous cell carcinoma].

Quan Hao1, Xiao-Qin Du, Xin Fu, Jing Tian.   

Abstract

OBJECTIVE: To investigate the association between high mobility group box1 (HMGB1) and cervical squamous cell carcinoma (CSCC), and explore the role of HMGB1/RAGE pathway in the metastasis of CSCC.
METHODS: Levels of HMGB1 mRNA and RAGE mRNA in CSCC and normal cervical tissues were detected by real time quantitative polymerase chain reaction (qRT-PCR), and the level of HMGB1 protein was determined by immunohistochemistry and Western blotting.
RESULTS: The mRNA and protein expression of HMGB1 was significantly higher in CSCC than that in normal cervical tissue (P < 0.05), correlated with stage, invasion and metastasis (P < 0.05), but not with tumor size and differentiation (P > 0.05). The levels of RAGE mRNA and HMGB1 mRNA were both significantly higher (r = 0.663, P < 0.05) in metastatic CSCC in comparison with those in the non-metastatic cases.
CONCLUSION: HMGB1 is involved in the invasion and metastasis of CSCC, and HMGB1/RAGE pathway plays an important role in the metastasis of CSCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18788635

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  17 in total

1.  HMGB1 promotes lymphangiogenesis of human lymphatic endothelial cells in vitro.

Authors:  Yuanyuan Qiu; Ying Chen; Xin Fu; Lei Zhang; Jing Tian; Quan Hao
Journal:  Med Oncol       Date:  2010-12-22       Impact factor: 3.064

2.  Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma.

Authors:  Jiliang He; Peng Zhang; Qinghu Li; Dongsheng Zhou; Ping Liu
Journal:  Oncol Lett       Date:  2015-11-10       Impact factor: 2.967

3.  Correlation of HMGB1 expression to progression and poor prognosis of adenocarcinoma and squamous cell/adenosquamous carcinoma of gallbladder.

Authors:  Zilu Shi; Qian Huang; Jian Chen; Pengcheng Yu; Xiaosong Wang; Hong Qiu; Yijie Chen; Yangyang Dong
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

4.  Correlation of High Mobility Group Box-1 Protein (HMGB1) with Clinicopathological Parameters in Primary Retinoblastoma.

Authors:  Mithalesh Kumar Singh; Lata Singh; Neelam Pushker; Seema Sen; Anjana Sharma; Feeroj Ahamad Chauhan; Seema Kashyap
Journal:  Pathol Oncol Res       Date:  2015-06-30       Impact factor: 3.201

Review 5.  High-mobility group box 1 and cancer.

Authors:  Daolin Tang; Rui Kang; Herbert J Zeh; Michael T Lotze
Journal:  Biochim Biophys Acta       Date:  2010 Jan-Feb

6.  Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels.

Authors:  Xiugui Sheng; Xuelian Du; Xiaoling Zhang; Dapeng Li; Chunhua Lu; Qinshui Li; Zhifang Ma; Quqing Song; Cong Wang
Journal:  Croat Med J       Date:  2009-10       Impact factor: 1.351

7.  Life after death: targeting high mobility group box 1 in emergent cancer therapies.

Authors:  Z Sheng Guo; Zuqiang Liu; David L Bartlett; Daolin Tang; Michael T Lotze
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

8.  HMGB1 combining with tumor-associated macrophages enhanced lymphangiogenesis in human epithelial ovarian cancer.

Authors:  Wenqi Zhang; Jing Tian; Quan Hao
Journal:  Tumour Biol       Date:  2013-10-22

9.  The role of high mobility group box 1 (HMGB1) in colorectal cancer.

Authors:  Dinç Süren; Mustafa Yıldırım; Özlem Demirpençe; Vildan Kaya; Arsenal Sezgin Alikanoğlu; Nurullah Bülbüller; Mustafa Yıldız; Cem Sezer
Journal:  Med Sci Monit       Date:  2014-03-31

10.  Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients.

Authors:  Weiling He; Bing Tang; Dongjie Yang; Yuhuang Li; Wu Song; Tuckyun Cheang; Xinlin Chen; Yin Li; Lianzhou Chen; Wenhua Zhan; Wen Li; Yulong He
Journal:  World J Surg Oncol       Date:  2013-07-18       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.